Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00264381 · ClinicalTrials.gov registry record · Phase 4
Management of Superficial Thrombophlebitis
A Phase 4 study, sponsored by University of Oklahoma.
- Completed
- Registry status
- Phase 4
- Development phase
- 72
- Enrollment target
NCT00264381: Completed Phase 4 study, sponsored by University of Oklahoma.
NCT00264381 is a Phase 4 study that has completed, run by University of Oklahoma. The registered enrollment target is 72 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00264381, a Phase 4 study, has completed, sponsored by University of Oklahoma.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 72 participants
- Enrollment target
Study Summary
The purpose of this study is to test the hypothesis that Fragmin (dalteparin sodium) subcutaneously once daily for 7 days is more effective than Ibuprofen given orally three times daily for 7 days for the treatment of superficial thrombophlebitis (STP).
Primary Outcome
Thrombosis progression and deep vein thrombosis at day 14 by ultrasound testing
Interventions
- DRUG Dalteparin sodium injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2002-10 |
| Est. Completion | 2011-09 |
| Phase | Phase 4 |
What the finished NCT00264381 record still lists
NCT00264381 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 1 intervention - of which Dalteparin sodium injection is the first listed.
NCT00264381 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00264381 about?
NCT00264381 is a clinical study titled "Management of Superficial Thrombophlebitis". The purpose of this study is to test the hypothesis that Fragmin (dalteparin sodium) subcutaneously once daily for 7 days is more effective than Ibuprofen given orally three times daily for 7 days for the treatment of superficial thrombophlebitis (STP).
What is the current status of trial NCT00264381?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 72 participants. The study started on 2002-10. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00264381?
The interventions under investigation include: Dalteparin sodium injection (DRUG).
Who is sponsoring clinical trial NCT00264381?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00264381's enrollment target sits among peer trials
72 1035th of 2000 higher than 961 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia